A growing number of recovered coronavirus patients report hair loss. A Study Conducted by Dr. Natalie Lambert and Survivor Corps shows that 27% of patients recovering from COVID-19 reported hair loss as one of the lingering problems in a survey of more than 1,500 people. While CDC only identified 17 COVID-19 symptoms, survey found 98 possible symptoms. However, the hair loss may be tied to a condition called telogen effluvium.
A recent survey identified dozens of potential long-term coronavirus symptoms that had previously been unreported, including hair loss. The study was conducted by a doctor at the Indiana University School of Medicine and the grassroots COVID-19 survivor group Survivor Corps using a Facebook poll. While the Centers for Disease Control and Prevention recently identified only 17 persistent COVID-19 symptoms, the survey of more than 1,500 patients found 98 possible symptoms, according to Dr. Natalie Lambert, an associate research professor at the Indiana University school of medicine. “The new symptoms our study identified include severe nerve pain, difficulty concentrating, difficulty sleeping, blurry vision and even hair loss,” Lambert said in a written statement, New York Post wrote.
Theresa Cabrera was so ill with COVID-19 that she had to spend a month in the hospital this spring, much of that time sedated, intubated and on a ventilator. When she finally improved and was able to go home in May, the first thing she did was take a shower. That’s when she noticed her hair falling out. “It came out in my hands — still does,” said Cabrera, 54, who lives in Lake Hopatcong, New Jersey. She’s not alone. More than a quarter, or 27%, of patients recovering from COVID-19 reported hair loss as one of the lingering problems in a survey of more than 1,500 people in the Survivor Corp Facebook group. Members are sometimes called “long haulers” because they discuss long-term effects of the disease, according to Today.com.
The hair loss may be tied to a condition called telogen effluvium. It causes people who experience a stressful illness or other life event to shed hair. Telogen effluvium hair loss typically starts about three months after the stressful event, which would coincide with the pandemic’s peak. While there’s still a lot to learn about COVID-19, many members of the Survivor Corps group have reported difficulty in getting help from their doctors to manage less common coronavirus symptoms, FOX News wrote.
“We have seen a few people reporting it, but we don’t know if it is significant or not,” said Tim Spector, professor of genetic epidemiology at King’s College London and lead researcher of the Covid-19 symptom study. While the virus may be to blame, experts say there are other explanations. “A form of hair loss called telogen effluvium can result in temporary hair loss as a result of a number of triggers including fever and severe illness, which may explain some cases of hair loss reported with Covid-19 infection,” said Dr Tanya Bleiker, clincial vice president of the British Association of Dermatologists, according to The Guardian.
CDC stated that people with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have COVID-19: Fever or chills, Cough, Shortness of breath or difficulty breathing, Fatigue, Muscle or body aches, Headache, New loss of taste or smell, Sore throat, Congestion or runny nose, Nausea or vomiting, Diarrhea. It should be mentioned that, this list does not include all possible symptoms. CDC will continue to update this list as we learn more about COVID-19.
It should be mentioned that, preliminary clinical data indicate that severe acute respiratory syndrome coronavirus infection is associated with neurological and neuropsychiatric illness. A new study shows that some coronavirus patients suffered either temporary brain dysfunction, strokes, nerve damage or other serious brain effects. Another dozen patients observed in the study had swelling in their central nervous systems. “We’re seeing things in the way Covid-19 affects the brain that we haven’t seen before with other viruses,” said Michael Zandi, a senior author on the study.
Earlier this month, Synairgen plc, the respiratory drug discovery and development company which originated from research at the University of Southampton, announced positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. Researchers have announced the results of an initial trial which found the odds of Covid-19 patients not needing ventilation, or dying, while being treated in hospital were 79% better among those given SNG001 compared with those given a placebo. Read more.